Recent studies have centered on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and DA communication. While GIP stimulators are increasingly employed for addressing type 2 diabetes mellitus, their potential effects on reinforcement circuits, specifically governed by dopamine systems, are